Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Etrasimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 233,484Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Everest Medicines Publish Etrasimod's Phase III ENLIGHT UC Study
    Everest Medicines Publish Etrasimod's Phase III ENLIGHT UC Study

    09 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-09/everest-medicines-announces-publication-of-etrasimods-asian-multicenter-phase-iii-enlight-uc-study-es101002-results-in-the-lancet-gastroenterology

    PHARMIWEB
    09 Oct 2025
    Share Share
    Pfizer’s Velsipity faces stiff competition in UC market: reports
    Pfizer’s Velsipity faces stiff competition in UC market: reports

    04 Apr 2024

    // Andrea Park FIERCE PHARMA

    https://www.fiercepharma.com/marketing/pfizers-velsipity-poised-outpace-bms-zeposia-ulcerative-colitis-market-must-head-further

    Andrea Park FIERCE PHARMA
    04 Apr 2024
    Share Share
    Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau
    Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau

    10 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-announces-acceptance-of-velsipity-new-drug-application-in-macau-302084833.html

    PR NEWSWIRE
    10 Mar 2024
    Share Share
    Pfizer inflammatory bowel disease drug wins EU approval
    Pfizer inflammatory bowel disease drug wins EU approval

    20 Feb 2024

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-velsipityr-patients#:~:text=(NYSE%3A%20PFE)%20announced%20today,lost%20response%2C%20or%20were%20intolerant

    PRESS RELEASE
    20 Feb 2024
    Share Share
    Pfizer`s Velsipity (etrasimod) Receives Approval in Europe
    Pfizer`s Velsipity (etrasimod) Receives Approval in Europe

    16 Feb 2024

    // EMA

    https://www.ema.europa.eu/en/documents/overview/velsipity-epar-medicine-overview_en.pdf-0

    EMA
    16 Feb 2024
    Share Share
    Everest Medicines' Licensing Partner Pfizer Announces FDA Approves Etrasimod
    Everest Medicines' Licensing Partner Pfizer Announces FDA Approves Etrasimod

    15 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/everest-medicines-licensing-partner-pfizer-announces-us-fda-approves-etrasimod-for-adults-with-moderately-to-severely-active-ulcerative-colitis-301956907.html

    PR NEWSWIRE
    15 Oct 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.